These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23920003)

  • 1. Evaluating the predictive ability of sweat chloride.
    Heltshe SL; Rowe SM; Mayer-Hamblett N
    J Cyst Fibros; 2014 Jan; 13(1):118. PubMed ID: 23920003
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
    Heltshe SL; Mayer-Hamblett N; Rowe SM
    Chest; 2013 Oct; 144(4):1418. PubMed ID: 24081360
    [No Abstract]   [Full Text] [Related]  

  • 3. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ; Jones AM; Webb AK; Horsley AR
    Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 6. Response.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Oct; 144(4):1418-1419. PubMed ID: 24081359
    [No Abstract]   [Full Text] [Related]  

  • 7. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.
    McGarry ME; Nielson DW
    Chest; 2013 Oct; 144(4):e1-e4. PubMed ID: 24081349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
    Secunda KE; Guimbellot JS; Jovanovic B; Heltshe SL; Sagel SD; Rowe SM; Jain M
    Am J Respir Crit Care Med; 2020 Apr; 201(8):996-998. PubMed ID: 31841644
    [No Abstract]   [Full Text] [Related]  

  • 9. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
    Grasemann H; Ratjen F; Solomon M
    N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486
    [No Abstract]   [Full Text] [Related]  

  • 11. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
    Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Organoid Swelling and
    Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398
    [No Abstract]   [Full Text] [Related]  

  • 16. Newborn screening for cystic fibrosis: Is there benefit for everyone?
    Course CW; Hanks R
    Paediatr Respir Rev; 2019 Aug; 31():3-5. PubMed ID: 30956155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
    Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
    Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
    Konstan MW; Plant BJ; Elborn JS; Rodriguez S; Munck A; Ahrens R; Johnson C
    Pediatr Pulmonol; 2015 May; 50(5):447-55. PubMed ID: 25755212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.